Diurnal Group inks distribution accord with Er-Kim

29 June 2021

Adding to a string of recent distribution deals, UK specialty pharma firm Diurnal Group (AIM: DNL) says it has extended its distribution arrangements with Er-Kim, a partner for global biotech and pharma companies seeking to commercialize its products in Turkey, Europe and the Middle East, to include the distribution and marketing of Alkindi (hydrocortisone granules in capsules for opening) and Efmody (hydrocortisone modified-release hard capsules) in Bulgaria and Romania.

Under the terms of the deal, Er-Kim will get exclusive rights to distribute and market Alkindi and Efmody in Bulgaria and Romania. The combined market in both countries is estimated to be more than $13 million in pediatric adrenal insufficiency (AI) and adult congenital adrenal hyperplasia (CAH). Diurnal’s shares dipped over 1% to 63.60 pence on the news.

Alkindi already has marketing authorization in the European Union and is the first preparation of hydrocortisone (the synthetic version of cortisol) specifically designed for use in children suffering from AI, including the related condition CAH.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK